Collegium Pharmaceutical, Inc. $COLL Position Reduced by Eventide Asset Management LLC

Eventide Asset Management LLC trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 9.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,390,912 shares of the specialty pharmaceutical company’s stock after selling 250,489 shares during the period. Collegium Pharmaceutical makes up about 1.4% of Eventide Asset Management LLC’s portfolio, making the stock its 17th largest holding. Eventide Asset Management LLC owned 7.56% of Collegium Pharmaceutical worth $83,653,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Collegium Pharmaceutical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC raised its stake in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock valued at $2,120,000 after buying an additional 4,625 shares during the period. Jane Street Group LLC boosted its stake in Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after buying an additional 90,255 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Collegium Pharmaceutical by 44.8% during the second quarter. Envestnet Asset Management Inc. now owns 44,734 shares of the specialty pharmaceutical company’s stock valued at $1,323,000 after buying an additional 13,842 shares in the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Stock Down 1.4%

Shares of Collegium Pharmaceutical stock opened at $34.50 on Friday. The stock’s fifty day moving average is $44.37 and its 200-day moving average is $42.01. The firm has a market capitalization of $1.10 billion, a PE ratio of 20.18 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The company had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.77 EPS. Equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on COLL. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Needham & Company LLC lowered their price objective on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.